Verve Therapeutics, Inc.
DelistedCIK 1840574fmd_18CGTGNYSABE71EWZ8FJE53ZKBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Mar 31, 2025, 22 periods
Latest annual · FY2024
Millions- Operating income
- (229)
- Net income
- (199)
- Free cash flow
- (161)
Latest quarter · Q1 FY2025
Millions- Operating income
- (37)
- Net income
- (31)
- Free cash flow
- (29)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2019 to FY2024
- n/m
Verve Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$228.7 million | -$223.1 million | 10-K 2025-02-27 · proof | |
| Net income | -$198.7 million | -$200.1 million | 10-K 2025-02-27 · proof | |
| Cash from operating activities | -$157.7 million | -$149.5 million | 10-K 2025-02-27 · proof | |
| Free cash flow | -$161.4 million | -$158.8 million | 10-K 2025-02-27 · proof | |
| Total assets | $647.4 million | $752.7 million | -14% | 10-K 2025-02-27 · proof |
| Total liabilities | $154 million | $153.2 million | +0.5% | 10-K 2025-02-27 · proof |
| Cash and cash equivalents | $172.6 million | $206.2 million | -16.3% | 10-K 2025-02-27 · proof |
- What was Verve Therapeutics, Inc.'s operating income in fiscal 2024?
- Verve Therapeutics, Inc. reported operating income of -$228.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$223.1 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What was Verve Therapeutics, Inc.'s net income in fiscal 2024?
- Verve Therapeutics, Inc. reported net income of -$198.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$200.1 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What was Verve Therapeutics, Inc.'s cash from operating activities in fiscal 2024?
- Verve Therapeutics, Inc. reported cash from operating activities of -$157.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$149.5 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What was Verve Therapeutics, Inc.'s free cash flow in fiscal 2024?
- Verve Therapeutics, Inc. reported free cash flow of -$161.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$158.8 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What are Verve Therapeutics, Inc.'s total assets?
- As of Dec 31, 2024, Verve Therapeutics, Inc. reported total assets of $647.4 million, against $752.7 million a year earlier (-14%). Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What are Verve Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2024, Verve Therapeutics, Inc. reported total liabilities of $154 million, against $153.2 million a year earlier (+0.5%). Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
- What are Verve Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Verve Therapeutics, Inc. reported cash and cash equivalents of $172.6 million, against $206.2 million a year earlier (-16.3%). Source: the 10-K filed with the SEC on Feb 27, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1840574&period_type=annual&limit=5"Information only, not investment advice.